A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis

BACKGROUND: To evaluate the immunomodulating and clinical effects of nilotinib, a tyrosine kinase inhibitor, in a proof-of-concept study in spondyloarthritis (SpA) assessing the mast cell as potential novel therapeutic target in this disease. METHODS: Twenty eight patients with active peripheral (pS...

Descripción completa

Detalles Bibliográficos
Autores principales: Paramarta, Jacqueline E., Turina, Maureen C., Noordenbos, Troy, Heijda, Tanja F., Blijdorp, Iris C., Yeremenko, Nataliya, Baeten, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081668/
https://www.ncbi.nlm.nih.gov/pubmed/27784336
http://dx.doi.org/10.1186/s12967-016-1050-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081668/
https://www.ncbi.nlm.nih.gov/pubmed/27784336
http://dx.doi.org/10.1186/s12967-016-1050-2

Ejemplares similares